Health economics of treating haemophilia A with inhibitors

Haemophilia, Supplement

Volumn 11, Issue 1, 2005, Pages 11-17

  Knight, Chris ^a  

^a RTI HEALTH SOLUTIONS   (United States)

Author keywords

Cost; Haemophilia; Health economics; Inhibitors; Orthopaedic surgery; Recombinant factor VIIa

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 ANTIBODY; HEMOSTATIC AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ARTHROPATHY; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG COST; DRUG MEGADOSE; ECONOMIC EVALUATION; HEALTH CARE COST; HEMOPHILIA A; HUMAN; JOINT PROSTHESIS; LONG TERM CARE; ORTHOPEDIC SURGERY; PLASMAPHERESIS; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; REVIEW; VIRUS INFECTION;

EID: 27744480353     PISSN: 13550691     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2005.01153.x     Document Type: Review

References (35)

1. Soucie J, Evatt B, Jackson D. Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators. Am J Hematol 1998; 59: 288-94.
2. Molho P, Rolland N, Lebrun T et al. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. Haemophilia 2000; 6: 23-32.
3. Kern M, Blanchette V, Stain AM, Einarson TR, Feldman BM. Clinical and cost implications of target joints in Canadian boys with severe hemophilia A. J Pediatr 2004; 145: 628-34.
4. Ross-Degnan D, Soumerai SB, Avorn J, Bohn RL, Bright R, Aledort LM. Hemophilia home treatment: economic analysis and implications for health policy. Int J Technol Assess Health Care 1995; 11: 327-44.
5. Ehrenforth S, Kreutz W, Scharer I et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8.
6. Lloyd Jones M, Wight J, Paisley S, Knight C. Control of bleeding in patients with haemophilia A with inhibitors: a systematic review. Haemophilia 2003; 9: 464-520.
7. Parameswaran R, Shapiro AD, Gill JC, Kessler CM. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005; 11: 100-6.
8. Goudemand J. Hemophilia. Treatment of patients with inhibitors: cost issues. Haemophilia 1999; 5: 397-401.
9. Gringeri A, Mantovani LG, Scalone L, Mannucci PM, COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358-63.
10. Auerswald G, Von Depka Prondzinski M, Ehlken B et al. Treatment patterns and cost-of-illness of severe haemophilia in patients with inhibitors in Germany. Haemophilia 2004; 10: 499-508.
11. Brackmann HH, Oldenberg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors - twenty years 'Bonn' protocol. Vox Sang 1996; 70(Suppl. 1): 30-5.
12. Berntorp E, Astermark J, Carlborg E. Immune tolerance induction and the treatment of hemophilia. Malmo protocol update. Haematologica 2000; 85(Suppl. 10): 48-50.
13. DiMichele DM, Kroner BL. Analysis of the North American Immune Tolerance Registry (NAITR) 1993-1997: current practice implications. ISTH Factor VIII/IX Subcommittee Members. Vox Sang 1999; 77(Suppl. 1): 31-2.
14. World Health Organization. Delivery of Treatment for Haemophilia. Report of a joint WHO/WFH/ISTH meeting, London, UK. 11-13 February 2002. Published online at http://whqlibdoc.who.int/hq/2002/WHO_WFH_ISTH_WG_02.6.pdf. Accessed June 2005.
15. Petrini P, Chambost H, Nemes L. Towards the goal of prophylaxis: experience and treatment strategies from Sweden, France and Hungary. Haemophilia 2004; 10(Suppl. 4): 94-6.
16. Young G, McDaniel M, Nugent DJ. Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors. Haemophilia 2005; 11: 203-7.
17. Chang H, Sher GD, Blanchette VS, Teitel JM. The impact of inhibitors on the cost of clotting factor replacement therapy in haemophilia A in Canada. Haemophilia 1999; 5: 247-52.
18. Bohn RL, Aledort LM, Putnam KG, Ewenstein BM, Mogun H, Avorn J. The economic impact of factor VIII inhibitors in patients with haemophilia. Haemophilia 2004; 10: 63-8.
19. Ekert H, Brewin T, Boey W, Davey P, Tilden D. Cost-utility analysis of recombinant factor VIIa (NovoSeven®) in six children with long-standing inhibitors to factor VIII or IX. Haemophilia 2001; 7: 279-85.
20. Odeyemi IAO, Guest JF. Economic Impact of Recombinant Activated Factor VII Compared to Activated Prothrombin Complex Concentrate in the Hospital Treatment of a Mild to Moderate Bleed among Adult Haemophilia Patients with Inhibitors in the UK [Abstract]. XVIII Congress of the International Society on Thrombosis and Haemostasis, Paris, 6-8 July 2001.
21. Odeyemi IAO, Guest JF. Modelling the economic impact of recombinant activated Factor VII compared to activated prothrombin complex concentrate in the home treatment of a mild to moderate bleed in adults with inhibitors to clotting factors VIII and IX. J Med Econ 2002; 5: 119-33.
22. Putnam KG, Bohn RL, Ewenstein BM, Winkelmayer WC, Avorn J. A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors. Haemophilia 2005; 11: 261-9.
23. Colowick AB, Bohn RL, Avorn J, Ewenstein BM. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 2000; 96: 1698-702.
24. Knight C, Paisley S, Wight J, Jones ML. Economic modelling of different treatment strategies for haemophilia A with high-responding inhibitors. Haemophilia 2003; 9: 521-40.
25. Fischer K, Van der Bom JG, Molho P et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia 2002; 8: 745.
26. Steen Carlsson K, Höjgård S, Lindgren A et al. Costs of on-demand and prophylactic treatment for severe haemophilia in Norway and Sweden. Haemophilia 2004; 10: 515-26.
27. Rodriguez-Merchan EC, Rocino A. Literature review of surgery management in inhibitor patients. Haemophilia 2004; 10(Suppl. 2): 22-9.
28. Freedman J, Rand ML, Russell O et al. Immunoadsorption may provide a cost-effective approach to management of patients with inhibitors to FVIII. Transfusion 2003; 43: 1508-13.
29. Habermann B, Hochmuth K, Hovy L, Scharrer I, Kurth AHA. Management of haemophilic patients with inhibitors in major orthopaedic surgery by immuno-adsorption, substitution of factor VIII and recombinant factor VIIa (NovoSeven®): a single centre experience. Haemophilia 2004; 10: 705-12.
30. Ludlam CA, Smith MP, Morfini M, Gringeri A. A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: a pharmacokinetic and efficacy evaluation. Br J Haematol 2003; 120: 808-13.
31. Rodriguez-Merchan EC, Wiedel JD, Wallny T et al. Elective orthopaedic surgery for inhibitor patients. Haemophilia 2003; 9: 625-31.
32. Cohen I, Heim M, Martinowitz U, Chechick A. Orthopaedic outcome of total knee replacement in Haemophilia A. Haemophilia 2000; 6: 104-9.
33. Mishra V, Tjønnfjord GE, Paus AC, Vaaler S. Orthopaedic surgery in severe bleeding disorder: a low-volume, high-cost procedure. Haemophilia 2002; 8: 809-14.
34. Mishra V, Paus AC, Tjønnfjord GE. Surgery in patients with bleeding disorders - expensive treatment for a small group of patients. Tidsskr Nor Laegeforen 2005; 125: 883-5.
35. Green C, de Cock E. Cost consequences of orthopedic surgery in haemophilia patients with inhibitors. Value Health 2001; 4: 467-8.